文献速递淋巴瘤

帕博利珠单抗同步联合AVD方案治疗初治经典型霍奇金淋巴瘤

Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma.
PubMed 文献 · Blood · 2023-01-01

这项单臂研究评估帕博利珠单抗同步联合AVD方案(多柔比星、长春花碱、达卡巴嗪;APVD)治疗初治经典型霍奇金淋巴瘤的安全性与疗效,纳入30例患者。主要安全终点达标,前2周期未观察到显著治疗延迟;29例可评估患者最佳总缓解率100%、完全缓解率90%;中位随访2.1年时2年无进展生存率97%、总生存率100%。

要点

  • 30例初治经典型霍奇金淋巴瘤患者接受帕博利珠单抗同步联合AVD方案治疗,主要安全终点达标。
  • 12例发生3/4级非血液学不良事件,最常见为发热性中性粒细胞减少和感染/脓毒症。
  • 29例可评估患者最佳总缓解率100%、完全缓解率90%,2年无进展生存率97%、总生存率100%。

核心结论

  • 帕博利珠单抗同步联合AVD方案治疗初治经典型霍奇金淋巴瘤显示出有前景的安全性和疗效,但可能在部分患者中产生假性PET表现。

研究设计与样本

  • 单臂研究,纳入30例初治经典型霍奇金淋巴瘤患者,接受帕博利珠单抗同步联合AVD方案(多柔比星、长春花碱、达卡巴嗪;APVD)治疗。
  • 试验注册号为NCT03331341。

主要发现

  • 主要安全终点达标,前2个周期未观察到显著的治疗延迟。
  • 12例患者发生3级或4级非血液学不良事件,最常见为发热性中性粒细胞减少和感染/脓毒症。
  • 3例患者观察到3级或4级免疫相关不良事件,包括丙氨酸氨基转移酶升高和天冬氨酸氨基转移酶升高;1例患者发生1次2级结肠炎和关节炎。
  • 6例患者因不良事件至少遗漏1次帕博利珠单抗给药,主要因2级或以上转氨酶升高。
  • 29例可评估疗效患者中,最佳总缓解率为100%,完全缓解率为90%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Concurrent administration of pembrolizumab with chemotherapy in untreated classic Hodgkin lymphoma (CHL) has not been studied previously. To investigate this combination, we conducted a single-arm study of concurrent pembrolizumab with AVD (doxorubicin, vinblastine, and dacarbazine; APVD) for untreated CHL. We enrolled 30 patients and met the primary safety end point with no observed significant treatment delays in the first 2 cycles. Twelve patients experienced grade 3 or 4 nonhematologic adverse events (AEs), most commonly febrile neutropenia and infection/sepsis. Grade 3 or 4 immune-related AEs, including alanine aminotransferase elevation and aspartate aminotransferase elevation were observed in 3 patients. One patient experienced an episode of grade 2 colitis and arthritis. Six patients missed at least 1 dose of pembrolizumab because of AEs, primarily grade 2 or higher transaminitis. Among 29 response-evaluable patients, the best overall response rate was 100% and the complete response rate was 90%. With a median follow-up of 2.1 years, the 2-year progression-free survival (PFS) and overall survival were 97% and 100%, respectively. To date, no patient who has withheld or discontinued pembrolizumab because of toxicity has progressed. Clearance of circulating tumor DNA (ctDNA) was associated with superior PFS when measured after cycle 2 and at the end of treatment (EOT). None of the 4 patients with persistent uptake by fluorodeoxyglucose positron emission tomography (PET) at EOT yet negative ctDNA have relapsed to date. Concurrent APVD shows promising safety and efficacy but may yield spurious PET findings in some patients. This trial was registered at www.clinicaltrials.gov as #NCT03331341.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Lynch RC, Ujjani CS, Poh C, et al. Concurrent pembrolizumab with AVD for untreated classic Hodgkin lymphoma. Blood. 2023. PMID: 36913694. doi:10.1182/blood.2022019254

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。